Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
It's time for a minimum synoptic operation template in patients undergoing laparoscopic cholecystectomy: a systematic review.
O'Connor N, Sugrue M, Melly C, McGeehan G, Bucholc M, Crawford A, O'Connor P, Abu-Zidan F, Wani I, Balogh ZJ, Shelat VG, Tebala GD, De Simone B, Eid HO, Chirica M, Fraga GP, Di Saverio S, Picetti E, Bonavina L, Ceresoli M, Fette A, Sakakushe B, Pikoulis E, Coimbra R, Ten Broek R, Hecker A, Leppäniemi A, Litvin A, Stahel P, Tan E, Koike K, Catena F, Pisano M, Coccolini F, Johnston A. O'Connor N, et al. World J Emerg Surg. 2022 Mar 17;17(1):15. doi: 10.1186/s13017-022-00411-5. World J Emerg Surg. 2022. PMID: 35296354 Free PMC article.
Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.
Bourgeois W, Cutler JA, Aubrey BJ, Wenge DV, Perner F, Martucci C, Henrich JA, Klega K, Nowak RP, Donovan KA, Boileau M, Wen Y, Hatton C, Apazidis AA, Olsen SN, Kirmani N, Pikman Y, Pollard JA, Perry JA, Sperling AS, Ebert BL, McGeehan GM, Crompton BD, Fischer ES, Armstrong SA. Bourgeois W, et al. Blood. 2024 Apr 11;143(15):1513-1527. doi: 10.1182/blood.2023021105. Blood. 2024. PMID: 38096371
The MLL-Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML.
Rasouli M, Blair H, Troester S, Szoltysek K, Cameron R, Ashtiani M, Krippner-Heidenreich A, Grebien F, McGeehan G, Zwaan CM, Heidenreich O. Rasouli M, et al. Hemasphere. 2023 Jul 27;7(8):e935. doi: 10.1097/HS9.0000000000000935. eCollection 2023 Aug. Hemasphere. 2023. PMID: 37520776 Free PMC article.
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.
Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, Thirman MJ, Patel MR, Dickens DS, Shenoy S, Shukla N, Kantarjian H, Armstrong SA, Perner F, Perry JA, Rosen G, Bagley RG, Meyers ML, Ordentlich P, Gu Y, Kumar V, Smith S, McGeehan GM, Stein EM. Issa GC, et al. Nature. 2023 Mar;615(7954):920-924. doi: 10.1038/s41586-023-05812-3. Epub 2023 Mar 15. Nature. 2023. PMID: 36922593 Free PMC article. Clinical Trial.
MEN1 mutations mediate clinical resistance to menin inhibition.
Perner F, Stein EM, Wenge DV, Singh S, Kim J, Apazidis A, Rahnamoun H, Anand D, Marinaccio C, Hatton C, Wen Y, Stone RM, Schaller D, Mowla S, Xiao W, Gamlen HA, Stonestrom AJ, Persaud S, Ener E, Cutler JA, Doench JG, McGeehan GM, Volkamer A, Chodera JD, Nowak RP, Fischer ES, Levine RL, Armstrong SA, Cai SF. Perner F, et al. Nature. 2023 Mar;615(7954):913-919. doi: 10.1038/s41586-023-05755-9. Epub 2023 Mar 15. Nature. 2023. PMID: 36922589 Free PMC article. Clinical Trial.
64 results